Hemolytic anemia risk factors: Difference between revisions

Jump to navigation Jump to search
Line 6: Line 6:


==Overview==
==Overview==
Risks factors for hemolytic anemia involve insults to [[red blood cells]] or defects within [[red blood cells''. Broadly, the risks factors can be categorized as oxidative stress, mechanical injury, and genetic ocnidtions.
Risks factors for hemolytic anemia involve insults to [[red blood cells]] or defects within [[red blood cells]]. Broadly, the risks factors can be categorized as oxidative stress, mechanical injury, and genetic conditions.


==Risk Factors==
==Risk Factors==

Revision as of 19:17, 26 October 2017

Hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT Scan

MRI Scan

Echocardiography or Ultrasound

Imaging Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic anemia risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic anemia risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic anemia risk factors

CDC on Hemolytic anemia risk factors

Hemolytic anemia risk factors in the news

Blogs on Hemolytic anemia risk factors

Directions to Hospitals Treating Hemolytic anemia

Risk calculators and risk factors for Hemolytic anemia risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Risks factors for hemolytic anemia involve insults to red blood cells or defects within red blood cells. Broadly, the risks factors can be categorized as oxidative stress, mechanical injury, and genetic conditions.

Risk Factors

Oxidative stress in the setting of G6PD deficiency:[1]

  • Use of primiquine for malaria treatment
  • Use of dapsone for PCP or leprosy treatment
  • Consumption of fava beans as part of a Mediterranean diet
  • Use of sulfa drugs like trimethoprim-sulfamethoxazole for treatment of skin, urinary tract, or other infections
  • Use of phenazopyridine for alleviating symptoms of dysuria
  • Use of nitrofurantoin for treatment of a urinary tract infection

Mechanical damage-related risk factors:

  • Presence of a mechanical mitral or aortic valve[2]
  • High shear stress from ECMO circuit in patients undergoing cardiac surgery or with hypoxic respiratory failure[2]
  • Presence of left ventricular assist device for end-stage heart failure[3]

Genetic conditions affecting red blood cells:

  • Hereditary spherocytosis
  • Hereditary elliptocytosis
  • Paroxysmal nocturnal hemoglobinuria
  • Sickle cell disease[4]

References

  1. Luzzatto L, Seneca E (2014). "G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications". Br J Haematol. 164 (4): 469–80. doi:10.1111/bjh.12665. PMC 4153881. PMID 24372186.
  2. 2.0 2.1 Vermeulen Windsant IC, de Wit NC, Sertorio JT, van Bijnen AA, Ganushchak YM, Heijmans JH; et al. (2014). "Hemolysis during cardiac surgery is associated with increased intravascular nitric oxide consumption and perioperative kidney and intestinal tissue damage". Front Physiol. 5: 340. doi:10.3389/fphys.2014.00340. PMC 4157603. PMID 25249983.
  3. Wuschek A, Iqbal S, Estep J, Quigley E, Richards D (2015). "Left ventricular assist device hemolysis leading to dysphagia". World J Gastroenterol. 21 (18): 5735–8. doi:10.3748/wjg.v21.i18.5735. PMC 4427699. PMID 25987800.
  4. Gaines AR, Lee-Stroka H, Byrne K, Scott DE, Uhl L, Lazarus E; et al. (2009). "Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model". Transfusion. 49 (6): 1050–8. doi:10.1111/j.1537-2995.2008.02083.x. PMC 3418653. PMID 19220820.

Template:WS Template:WH